Table 4

Chemotherapeutic efficacy of Taxol and Adriamycin on NNK-induced lung tumorigenesis in p53 transgenic mice

GroupGenotypeNo. of miceTreatmentaTumor incidenceTumor multiplicityTumor vol. (mm3)/mouseDecrease in tumor vol. (%)
1 p53 wt/wt 18NNK100%6.7 ± 2.94.6 ± 2.5
2 p53 Val135/wt 19NNK100%16.6 ± 4.425.4 ± 12.5
3 p53 wt/wt 17NNK/Tax100%5.8 ± 2.61.8 ± 0.9b61.4
4 p53 Val135/wt 17NNK/Tax100%11.0 ± 4.85.8 ± 3.0b77.3
5 p53 wt/wt 19NNK/Adr100%5.4 ± 2.61.5 ± 0.4c66.7
6 p53 Val135/wt 19NNK/Adr100%13.2 ± 4.67.0 ± 3.0c72.5
  • a At 6 weeks of age, all of the animals (equal numbers of males and females) were given two i.p. injections of NNK (100 mg/kg body weight) 1 week apart. After 16 weeks’ exposure, mice in groups 1 and 2 were given vehicle control. Mice in groups 3 and 4 were given Taxol (20 mg/kg, in 0.2 ml of ethanol/Cremophor EL) and the mice in groups 5 and 6 were given Adriamycin (5 mg/kg in 0.2 ml PBS). Both Taxol and Adriamycin were given twice a week for three weeks.

  • b P < 0.0001, significant regression of tumor volume compared with corresponding control groups.

  • c P < 0.0001, significantly different from the corresponding control groups.

  • Tax, Taxol; Adr, Adriamycin.